Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Free Radic Biol Med ; 131: 282-298, 2019 02 01.
Article in English | MEDLINE | ID: mdl-30572012

ABSTRACT

The chromatin structure of the mammalian genome must facilitate both precisely-controlled DNA replication together with tightly-regulated gene transcription. This necessarily involves complex mechanisms and processes which remain poorly understood. It has long been recognised that the epigenetic landscape becomes established during embryonic development and acts to specify and determine cell fate. In addition, the chromatin structure is highly dynamic and allows for both cellular reprogramming and homeostatic modulation of cell function. In this respect, the functions of epigenetic "erasers", which act to remove covalently-linked epigenetic modifications from DNA and histones are critical. The enzymatic activities of the TET and JmjC protein families have been identified as demethylases which act to remove methyl groups from DNA and histones, respectively. Further, they are characterised as members of the Fe(II)- and 2-oxoglutarate-dependent dioxygenase superfamily. This provides the intriguing possibility that their enzymatic activities may be modulated by cellular metabolism, oxygen availability and redox-based mechanisms, all of which are likely to display dynamic cell- and tissue-specific patterns of flux. Here we discuss the current evidence for such [O2]- and redox-dependent regulation of the TET and Jmjc demethylases and the potential physiological and pathophysiological functional consequences of such regulation.


Subject(s)
DNA/genetics , Epigenesis, Genetic , Histones/genetics , Jumonji Domain-Containing Histone Demethylases/genetics , Mixed Function Oxygenases/genetics , Oxygen/metabolism , Proto-Oncogene Proteins/genetics , Animals , Cell Differentiation , Cell Lineage/drug effects , Cell Lineage/genetics , Cellular Reprogramming , DNA/metabolism , DNA Methylation , Demethylation , Embryo, Mammalian , Histones/metabolism , Humans , Jumonji Domain-Containing Histone Demethylases/metabolism , Mixed Function Oxygenases/metabolism , Oxidation-Reduction , Oxygen/pharmacology , Proto-Oncogene Proteins/metabolism
2.
J Med Chem ; 58(17): 6803-18, 2015 Sep 10.
Article in English | MEDLINE | ID: mdl-26287310

ABSTRACT

A novel series of potent chiral inhibitors of histone deacetylase (HDAC) is described that contains an oxazoline capping group and a N-(2-aminophenyl)-benzamide unit. Among several new inhibitors of this type exhibiting Class I selectivity and potent inhibition of HDAC3-NCoR2, in vitro assays for the inhibition of HDAC1, HDAC2, and HDAC3-NCoR2 by N-(2-aminophenyl)-benzamide 15k gave respective IC50 values of 80, 110, and 6 nM. Weak inhibition of all other HDAC isoforms (HDAC4, 5, 6, 7, and 9: IC50 > 100 000 nM; HDAC8: IC50 = 25 000 nM; HDAC10: IC50 > 4000 nM; HDAC11: IC50 > 2000 nM) confirmed the Class I selectivity of 15k. 2-Aminoimidazolinyl, 2-thioimidazolinyl, and 2-aminooxazolinyl units were shown to be effective replacements for the pyrimidine ring present in many other 2-(aminophenyl)-benzamides previously reported, but the 2-aminooxazolinyl unit was the most potent in inhibiting HDAC3-NCoR2. Many of the new HDAC inhibitors showed higher solubilities and lower binding to human serum albumin than that of Mocetinostat. Increases in histone H3K9 acetylation in the human cell lines U937 and PC-3 was observed for all three oxazolinyl inhibitors evaluated; those HDAC inhibitors also lowered cyclin E expression in U937 cells but not in PC-3 cells, indicating underlying differences in the mechanisms of action of the inhibitors on those two cell lines.


Subject(s)
Anilides/chemistry , Benzamides/chemistry , Histone Deacetylase Inhibitors/chemistry , Histone Deacetylases/metabolism , Oxazoles/chemistry , Acetylation , Anilides/chemical synthesis , Anilides/pharmacology , Apoptosis/drug effects , Benzamides/chemical synthesis , Benzamides/pharmacology , Cell Cycle/drug effects , Cell Line , Cell Line, Tumor , Histone Deacetylase Inhibitors/chemical synthesis , Histone Deacetylase Inhibitors/pharmacology , Humans , Imidazolines/chemical synthesis , Imidazolines/chemistry , Imidazolines/pharmacology , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Oxazoles/chemical synthesis , Oxazoles/pharmacology , Permeability , Protein Binding , Pyrimidines/pharmacology , Serum Albumin/metabolism , Solubility , Stereoisomerism , Structure-Activity Relationship
3.
J Med Chem ; 56(15): 6156-74, 2013 Aug 08.
Article in English | MEDLINE | ID: mdl-23829483

ABSTRACT

The synthesis of a novel series of potent chiral inhibitors of histone deacetylase (HDAC) is described that contain a heterocyclic capping group and a N-(2-aminophenyl)benzamide unit that binds in the active site. In vitro assays for the inhibition of HDAC1, HDAC2, HDAC3-NCoR1, and HDAC8 by the N-(2-aminophenyl)benzamide 24a gave respective IC50 values of 930, 85, 12, and 4100 nM, exhibiting class I selectivity and potent inhibition of HDAC3-NCoR1. Both imidazolinone and thiazoline rings are shown to be effective replacements for the pyrimidine ring present in many other 2-(aminophenyl)benzamides previously reported, an example of each ring system at 1 µM causing an increase in histone H3K9 acetylation in the human cell lines Jurkat and HeLa and an increase in cell death consistent with induction of apoptosis. Inhibition of the growth of MCF-7, A549, DU145, and HCT116 cell lines by 24a was observed, with respective IC50 values of 5.4, 5.8, 6.4, and 2.2 mM.


Subject(s)
Aniline Compounds/chemical synthesis , Benzamides/chemical synthesis , Histone Deacetylase Inhibitors/chemical synthesis , Histone Deacetylases/metabolism , Acetylation , Aniline Compounds/chemistry , Aniline Compounds/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Apoptosis , Benzamides/chemistry , Benzamides/pharmacology , Catalytic Domain , Cell Line , Cell Line, Tumor , Drug Screening Assays, Antitumor , Histone Deacetylase Inhibitors/chemistry , Histone Deacetylase Inhibitors/pharmacology , Histones/metabolism , Humans , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Molecular Docking Simulation , Protein Binding , Stereoisomerism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...